SKP2 and acute lymphoblastic leukemia: Treatment of several human T-ALL cell lines, all exhibiting elevated SKP2 levels (Fig. S8E), showed a significant dose-dependent inhibition of cell proliferation in cell lines with high Notch activation and also in cell lines established from high-risk and relapsed patients, which have little or no Notch signaling, such as CEM and Loucy (Fig. 6a), suggesting that SKP2 inhibition is effective also in Notch-independent highly proliferative leukemia subtypes.